Hepatitis Monthly

Published by: Kowsar

Association between Serum Cytokeratin-18 Neoepitope M30 (CK-18 M30) Levels and Chronic Hepatitis B: A Meta-Analysis

Changfei Li 1 , Shousheng Liu 2 , 3 , Linlin Lu 2 , 3 , Quanjiang Dong 3 , 4 , Shiying Xuan 1 , 2 , 4 , * and Yongning Xin 1 , 2 , 4 , 5 , **
Authors Information
1 Medical College of Qingdao University, Qingdao 266071, China
2 Digestive Disease Key Laboratory of Qingdao, Qingdao 266071, China
3 Central Laboratories, Qingdao Municipal Hospital, Qingdao 266071, China
4 Department of Gastroenterology, Qingdao Municipal Hospital, Qingdao, Shandong Province, China
5 Department of Infectious Disease, Qingdao Municipal Hospital, Qingdao 266011, China
Corresponding Authors:
Article information
  • Hepatitis Monthly: April 2018, 18 (4); e64152
  • Published Online: April 30, 2018
  • Article Type: Research Article
  • Received: November 17, 2017
  • Accepted: April 20, 2018
  • DOI: 10.5812/hepatmon.64152

To Cite: Li C, Liu S, Lu L, Dong Q, Xuan S, et al. Association between Serum Cytokeratin-18 Neoepitope M30 (CK-18 M30) Levels and Chronic Hepatitis B: A Meta-Analysis, Hepat Mon. 2018 ;18(4):e64152. doi: 10.5812/hepatmon.64152.

Abstract
Copyright © 2018, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnote
References
  • 1. Ganem D, Prince AM. Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med. 2004;350(11):1118-29. doi: 10.1056/NEJMra031087. [PubMed: 15014185].
  • 2. Zamor PJ, deLemos AS, Russo MW. Viral hepatitis and hepatocellular carcinoma: etiology and management. J Gastrointest Oncol. 2017;8(2):229-42. doi: 10.21037/jgo.2017.03.14. [PubMed: 28480063].
  • 3. Bitton Alaluf M, Shlomai A. New therapies for chronic hepatitis B. Liver Int. 2016;36(6):775-82. doi: 10.1111/liv.13086. [PubMed: 26854115].
  • 4. Kang SM, Shin MJ, Kim JH, Oh JW. Proteomic profiling of cellular proteins interacting with the hepatitis C virus core protein. Proteomics. 2005;5(8):2227-37. doi: 10.1002/pmic.200401093. [PubMed: 15846844].
  • 5. Zeng DW, Dong J, Liu YR, Jiang JJ, Zhu YY. Noninvasive models for assessment of liver fibrosis in patients with chronic hepatitis B virus infection. World J Gastroenterol. 2016;22(29):6663-72. doi: 10.3748/wjg.v22.i29.6663. [PubMed: 27547009].
  • 6. Invernizzi F, Vigano M, Grossi G, Lampertico P. The prognosis and management of inactive HBV carriers. Liver Int. 2016;36 Suppl 1:100-4. doi: 10.1111/liv.13006. [PubMed: 26725905].
  • 7. Branchi F, Conti CB, Baccarin A, Lampertico P, Conte D, Fraquelli M. Non-invasive assessment of liver fibrosis in chronic hepatitis B. World J Gastroenterol. 2014;20(40):14568-80. doi: 10.3748/wjg.v20.i40.14568. [PubMed: 25356021].
  • 8. Pan CQ, Zhang JX. Natural History and Clinical Consequences of Hepatitis B Virus Infection. Int J Med Sci. 2005;2(1):36-40. [PubMed: 15968338].
  • 9. Jieanu CF, Ungureanu BS, Sandulescu DL, Gheonea IA, Tudorascu DR, Ciurea ME, et al. Quantification of liver fibrosis in chronic hepatitis B virus infection. J Med Life. 2015;8(3):285-90. [PubMed: 26351528].
  • 10. Bedossa P, Carrat F. Liver biopsy: the best, not the gold standard. J Hepatol. 2009;50(1):1-3. doi: 10.1016/j.jhep.2008.10.014. [PubMed: 19017551].
  • 11. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003;38(6):1449-57. doi: 10.1016/j.hep.2003.09.022. [PubMed: 14647056].
  • 12. Ijaz B, Ahmad W, Javed FT, Gull S, Hassan S. Revised cutoff values of ALT and HBV DNA level can better differentiate HBeAg (-) chronic inactive HBV patients from active carriers. Virol J. 2011;8:86. doi: 10.1186/1743-422X-8-86. [PubMed: 21352567].
  • 13. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518-26. doi: 10.1053/jhep.2003.50346. [PubMed: 12883497].
  • 14. Fitzpatrick E, Mitry RR, Quaglia A, Hussain MJ, DeBruyne R, Dhawan A. Serum levels of CK18 M30 and leptin are useful predictors of steatohepatitis and fibrosis in paediatric NAFLD. J Pediatr Gastroenterol Nutr. 2010;51(4):500-6. doi: 10.1097/MPG.0b013e3181e376be. [PubMed: 20808246].
  • 15. Parikh P, Ryan JD, Tsochatzis EA. Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection. Ann Transl Med. 2017;5(3):40. doi: 10.21037/atm.2017.01.28. [PubMed: 28251119].
  • 16. Lee JE, Lee JM, Lee KB, Yoon JH, Shin CI, Han JK, et al. Noninvasive assessment of hepatic fibrosis in patients with chronic hepatitis B viral infection using magnetic resonance elastography. Korean J Radiol. 2014;15(2):210-7. doi: 10.3348/kjr.2014.15.2.210. [PubMed: 24643284].
  • 17. Eren F, Yilmaz Y, Kose S, Ozdemir FT, Yonal O, Kurt R, et al. Caspase-cleaved fragments of cytokeratin 18 in patients with chronic hepatitis B. Clin Chim Acta. 2010;411(23-24):2029-32. doi: 10.1016/j.cca.2010.08.035. [PubMed: 20807521].
  • 18. Cave M, Falkner KC, Henry L, Costello B, Gregory B, McClain CJ. Serum cytokeratin 18 and cytokine elevations suggest a high prevalence of occupational liver disease in highly exposed elastomer/polymer workers. J Occup Environ Med. 2011;53(10):1128-33. doi: 10.1097/JOM.0b013e31822cfd68. [PubMed: 21915069].
  • 19. Rosso C, Caviglia GP, Abate ML, Vanni E, Mezzabotta L, Touscoz GA, et al. Cytokeratin 18-Aspartate396 apoptotic fragment for fibrosis detection in patients with non-alcoholic fatty liver disease and chronic viral hepatitis. Dig Liver Dis. 2016;48(1):55-61. doi: 10.1016/j.dld.2015.09.008. [PubMed: 26514735].
  • 20. Yang ZH, Yang SX, Qin CZ, Chen YX. Clinical values of elevated serum cytokeratin-18 levels in hepatitis: a meta-analysis. Hepat Mon. 2015;15(5). e25328. doi: 10.5812/hepatmon.15(5)2015.25328. [PubMed: 26045704].
  • 21. Feldstein AE, Alkhouri N, De Vito R, Alisi A, Lopez R, Nobili V. Serum cytokeratin-18 fragment levels are useful biomarkers for nonalcoholic steatohepatitis in children. Am J Gastroenterol. 2013;108(9):1526-31. doi: 10.1038/ajg.2013.168. [PubMed: 23752877].
  • 22. Liang J, Liu F, Wang F, Han T, Jing L, Ma Z, et al. A Noninvasive Score Model for Prediction of NASH in Patients with Chronic Hepatitis B and Nonalcoholic Fatty Liver Disease. Biomed Res Int. 2017;2017:8793278. doi: 10.1155/2017/8793278. [PubMed: 28349067].
  • 23. Shi J, Ying H, Du J, Shen B. Serum Sclerostin Levels in Patients with Ankylosing Spondylitis and Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Biomed Res Int. 2017;2017:9295313. doi: 10.1155/2017/9295313. [PubMed: 28553652].
  • 24. Papatheodoridis GV, Hadziyannis E, Tsochatzis E, Chrysanthos N, Georgiou A, Kafiri G, et al. Serum apoptotic caspase activity as a marker of severity in HBeAg-negative chronic hepatitis B virus infection. Gut. 2008;57(4):500-6. doi: 10.1136/gut.2007.123943. [PubMed: 18025069].
  • 25. Sumer S, Aktug Demir N, Kolgelier S, Cagkan Inkaya A, Arpaci A, Saltuk Demir L, et al. The Clinical Significance of Serum Apoptotic Cytokeratin 18 Neoepitope M30 (CK-18 M30) and Matrix Metalloproteinase 2 (MMP-2) Levels in Chronic Hepatitis B Patients with Cirrhosis. Hepat Mon. 2013;13(6). e10106. doi: 10.5812/hepatmon.10106. [PubMed: 24032040].
  • 26. Yilmaz B, Aktas B, Altinbas A, Ginis Z, Ozturk G, Ekiz F, et al. The Role of M30 in Predicting the Severity of Liver Fibrosis and Inflammation in Chronic Hepatitis B Patients. Hepat Mon. 2016;16(9). e35640. doi: 10.5812/hepatmon.35640. [PubMed: 27822256].
  • 27. Balkan A, Yilmaz N, Balkan Y, Koruk I, Orkmez M, Aydinli M, et al. Relationship between liver injury and serum cytokeratin 18 levels in asymptomatic hepatitis B virus carriers and in patients with chronic hepatitis B infection. Arab J Gastroenterol. 2017;18(2):98-103. doi: 10.1016/j.ajg.2017.05.008. [PubMed: 28579343].
  • 28. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell. 1982;31(1):11-24. [PubMed: 6186379].
  • 29. Linder S, Olofsson MH, Herrmann R, Ulukaya E. Utilization of cytokeratin-based biomarkers for pharmacodynamic studies. Expert Rev Mol Diagn. 2010;10(3):353-9. doi: 10.1586/erm.10.14. [PubMed: 20370591].
  • 30. Linder S, Havelka AM, Ueno T, Shoshan MC. Determining tumor apoptosis and necrosis in patient serum using cytokeratin 18 as a biomarker. Cancer Lett. 2004;214(1):1-9. doi: 10.1016/j.canlet.2004.06.032. [PubMed: 15331168].
  • 31. Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology. 2009;50(4):1072-8. doi: 10.1002/hep.23050. [PubMed: 19585618].
  • 32. Aida Y, Abe H, Tomita Y, Nagano T, Seki N, Sugita T, et al. Serum cytokeratin 18 fragment level as a noninvasive biomarker for non-alcoholic fatty liver disease. Int J Clin Exp Med. 2014;7(11):4191-8. [PubMed: 25550930].
  • 33. Chen J, Zhu Y, Zheng Q, Jiang J. Serum cytokeratin-18 in the diagnosis of non-alcoholic steatohepatitis: A meta-analysis. Hepatol Res. 2014;44(8):854-62. doi: 10.1111/hepr.12197. [PubMed: 23834322].
  • 34. Swiderska M, Jaroszewicz J, Parfieniuk-Kowerda A, Rogalska-Plonska M, Stawicka A, Panasiuk A, et al. Serum Cytokeratin 18 M30 Levels in Chronic Hepatitis B Reflect Both Phase and Histological Activities of Disease. Mediators Inflamm. 2017;2017:3480234. doi: 10.1155/2017/3480234. [PubMed: 28827897].
  • 35. Oliveira VO, Oliveira JP, Franca EV, Brito HL, Nascimento TV, Franca A. Advanced liver injury in patients with chronic hepatitis b and viral load below 2,000 IU/mL. Rev Inst Med Trop Sao Paulo. 2016;58:65. doi: 10.1590/S1678-9946201658065. [PubMed: 27680170].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments